Business Context and Reporting Period
This Form 8-K is a current report filed by Aquinox Pharmaceuticals, Inc. (not Neurogene Inc.) on March 23, 2017. The filing addresses corporate governance changes, specifically the appointment of new directors and their associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Board Retainer: $35,000 per director.
- Meeting Fee: $500 per in-person regular board meeting.
- Committee Retainers: $3,750 for the Nominating and Corporate Governance Committee; $5,500 for the Compensation Committee.
- Stock Options: 18,000 shares initially (vesting over 3 years); 9,000 shares annually thereafter (vesting over 1 year).
Material Changes
The material change reported is the appointment of two new Class III and Class II directors:
- Dr. Kelvin Neu: Appointed as a Class III Director and member of the Nominating and Corporate Governance Committee.
- Dr. Richard Levy: Appointed as a Class II Director and member of the Compensation Committee.
Both appointments are effective until the respective annual meetings of stockholders or until their successors are elected.
Outlook, Risks, and Unusual Items
The filing details the execution of standard indemnification agreements for the new directors, covering legal expenses, judgments, and fines. The company confirmed there are no undisclosed family relationships or related person transactions involving the new directors. No forward-looking guidance, operational risks, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the correct registrant name is Aquinox Pharmaceuticals, Inc. (the input metadata incorrectly listed Neurogene Inc.).
- Confirm the vesting schedules for the 18,000 initial stock options and subsequent 9,000 annual grants.
- Review the referenced Form S-1 (No. 333-193615) for the full text of the standard indemnification agreement.
- Check subsequent filings for the formal election of these directors at the 2017 Annual Meeting of Stockholders.